Discovery Laboratories announced that the FDA has approved Surfaxin (lucinactant intratracheal suspension) for prevention of respiratory distress syndrome (RDS) in high-risk premature infants.
Vertex announced final results from the Phase 3 ENVISION study of Kalydeco (VX-770, ivacaftor), a drug being evaluated to target the G551D protein mutation that causes cystic fibrosis (CF).
Vertex Pharmaceuticals announced positive results from its Phase 3 ENVISION study of VX-770 for the treatment of cystic fibrosis (CF) among children ages 6-11 with at least one copy of the G551D mutation in the CFTR gene.
Vertex announced results from its Phase 3 study of VX-770 for the treatment of CF caused by a mutation in the G551D gene.
PTC Therapeutics announced it has completed enrollment of a Phase 3 trial of ataluren in patients with nonsense mutation cystic fibrosis (nmCF).
Inspire Pharmaceuticals announced results from its first Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis (CF).
Vertex announced the results from its Phase 2 study of VX-770 for the treatment of cystic fibrosis (CF).
